Yamaguchi et al developed a hazard ratio based on 4 clinical and molecular factors that can predict survival in a patient with an adenocarcinoma of the lung. The authors are from the University of Sao Paulo, the Institute of Advances in Medicine (Sao Paulo), Duke University and the Veterans Affairs Medical Center in Durham.